Modulation of Therapeutic Response
Modulation of Therapeutic Response
批准号:
6433342
负责人:
JAMES B MITCHELL
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
MCF7 cell breast neoplasms camptothecin cell cycle cellular oncology combination cancer therapy drug screening /evaluation lung neoplasms mitoxantrone neoplasm /cancer chemotherapy neoplasm /cancer radiation therapy paclitaxel prostate neoplasms radiation sensitivity radiosensitizer tissue /cell culture
中文摘要
为了改善癌症的治疗,人们对改变辐射损伤给予了相当大的关注。该项目的主要目标是继续定义和理解独特的肿瘤生理学、解剖学、细胞和分子过程的那些方面,这些方面最终定义了肿瘤的本质,从而使特定剂量的电离辐射在使用时更加有效。实现这一目标的一种方法是研究电离辐射与各种化疗药物的相互作用,以评估是否可以使肿瘤更敏感。我们先前证明,用紫杉醇治疗多种人类肿瘤细胞系可诱导细胞周期的G2/M(细胞周期的放射敏感期)阻滞,从而导致显著的放射敏感化。因此,将这些临床前信息转化为结合放疗和紫杉醇治疗头颈癌的临床试验目前正在放射肿瘤科进行。我们已经测试了其他化疗药物,包括喜树碱衍生物、米托蒽醌和UCN-01。米托蒽醌和UCN-01均未发现对多种人类肿瘤细胞系有明显的放射致敏作用。虽然喜树碱衍生物被发现具有放射致敏性,但其固有的细胞毒性很可能会阻止它们在临床放射治疗中使用。最近的研究集中在MGI-114,一种新的烷基化倍半萜类化合物,在体外和体内模型中都显示出细胞毒性。我们已经证明,MGI-114选择性地使人乳腺和结肠细胞系对辐射致敏,并表明这种致敏与S期细胞周期阻滞有关。我们还启动了使用两种间变性甲状腺癌细胞系的研究,试图确定可能使这些细胞系放射敏感的药物。在大约8种不同的药物评估中,只有5-碘脱氧尿苷的剂量修饰因子约为2。众所周知,缺氧是辐射敏感性的主要决定因素。因此,我们正在使用几种小鼠肿瘤模型来研究肿瘤缺氧。我们的方法是使用当前的侵入性技术,并将信息扩展到正在开发的非侵入性方法,这样患者的肿瘤治疗概况就可以在个体的基础上进行优化。为此,我们使用了体外和体内存活技术、氧探针、免疫组织化学后的硝基咪唑固定、F-18硝基咪唑PET扫描、血氧水平测定(BOLD)核磁共振、电子顺磁共振(EPR)和Overhauser核磁共振。目前,我们正在比较/对比这些不同的技术,目标是最终将无创EPR或Overhauser核磁共振功能成像带入临床试验。我们获得的信息将教会我们如何以非侵入性的方式评估肿瘤中的氧状态,以实现最佳治疗。肿瘤内的基因表达作为氧状态、再灌注、电离辐射暴露和一般氧化应激的功能正在被研究,以确定那些在肿瘤细胞对电离辐射单独或与药理学药物联合使用的损伤的反应性和存活中重要的分子事件。目的是扩展我们对肿瘤微环境、生理学和分子生物学的知识,并将这些知识与非侵入性肿瘤研究方法联系起来,以便我们设计有效的治疗方案,使用放射与药物药物联合或串联。同样,我们预计研究放射治疗后的基因表达谱将有可能提供新的分子靶点,这些靶点可能被选择性地抑制和/或增强,从而调节辐射反应。
英文摘要
In the interest of improving cancer treatment, considerable attention has been placed on the modification of radiation damage. The major goal of this project continues to define and understand those aspects of unique tumor physiology, anatomy, cellular, and molecular processes that ultimately define the very nature of a tumor such that a particular dose of ionizing radiation, when used will be more effective. One means to that end is to investigate the interaction of ionizing radiation with a variety of chemotherapy agents to assess if tumors can be made more sensitive. We previously demonstrated that treatment of diverse human tumor cell lines with paclitaxel induced a block in G2/M of the cell cycle (radiosensitive phases of the cell cycle) which resulted in significant radiosensitization. As a consequence, translation of this pre-clinical information into a clinical trail combining radiation and paclitaxel in the treatment of head/neck cancer is currently underway in the Radiation Oncology Branch. We have tested other chemotherapeutic agents including camptothecin derivatives, mitoxantrone, and UCN-01. Neither mitoxantrone nor UCN-01 was found to significantly radiosensitize a variety of human tumor cell lines. While camptothecin derivatives were found to radiosensitize, their inherent cytotoxicity alone will most likely prevent them from being used in the clinic with radiation. Recent studies have centered on the agent MGI-114, a new alkylating sesquiterpenoid which has shown cytotoxicity in both in vitro and in vivo models. We have shown that MGI-114 selectively radiosensitizes human breast and colon cell lines to radiation with an indication that the sensitization is related to cell cycle blocks in S phase. We have also initiated studies using two anaplastic thyroid cancer cell lines in an attempt to identify agents that might radiosensitize these cell lines. Of approximately eight different agents evaluated only 5-iododeoxyuridine radiosensitized with a dose-modifying factor of approximately 2.It is well established that hypoxia is a major determinant of radiation sensitivity. Therefore, we are using several murine tumor models to study tumor hypoxia. Our approach is to use current invasive techniques and extend that information to non-invasive methods that are under development, such that patient tumor treatment profiles may be optimized on an individual basis. To that end we are using in vitro and in vivo survival techniques, oxygen probes, nitroimidazole fixation followed by immunohistochemistry, F-18 nitroimidazole PET scanning, blood oxygen level determination (BOLD) NMR, electron paramagnetic resonance (EPR), and Overhauser NMR. Presently we are comparing/contrasting these various techniques with the goal of ultimately bringing non-invasive EPR or Overhauser NMR functional imaging to clinical trial. The information we acquire will teach us how to assess oxygen status in a tumor in a non-invasive manner to effect optimum treatment. Gene expression within a tumor as a function of oxygen status, reperfusion, ionizing radiation exposure and general oxidative stress is being investigated to determine those molecular events that are important in the tumor cell responsiveness and survival to insult by ionizing radiation alone or in combination with pharmacologic agents using cDNA microarray technology. The aim is to extend our knowledge of tumor micro-environment, physiology, and molecular biology and to correlate such knowledge with non-invasive methods of studying tumors so that we design efficient and effective treatment protocols using radiation in combination or tandem with pharmacologic agents. Likewise, we anticipate that studying gene expression profiles following radiation treatment will potentially provide novel molecular targets that may be selectively inhibited and/or enhanced which will modulate the radiation response.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Modulation of Therapeutic Response
-
批准号:6947107
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JAMES B MITCHELL
-
依托单位:
Radiolysis, Photolysis, Sonolysis and Sonoprotection of
-
批准号:7331390
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JAMES B MITCHELL
-
依托单位:
Nitroxides as Protectors Against Oxidative Stress
-
批准号:7594762
-
项目类别:
-
资助金额:$63.51万
-
财政年份:--
-
负责人:JAMES B MITCHELL
-
依托单位:
NITROXIDES AS PROTECTORS AGAINST OXIDATIVE STRESS
-
批准号:6290749
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JAMES B MITCHELL
-
依托单位:
Nitroxides as Protectors Against Oxidative Stress
-
批准号:7292012
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JAMES B MITCHELL
-
依托单位:
Modulation of Therapeutic Response
-
批准号:7331383
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JAMES B MITCHELL
-
依托单位:
Modulation of Therapeutic Response
-
批准号:7292006
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JAMES B MITCHELL
-
依托单位:
Modulation of Therapeutic Response
-
批准号:7594757
-
项目类别:
-
资助金额:$63.51万
-
财政年份:--
-
负责人:JAMES B MITCHELL
-
依托单位:
Modulation of Therapeutic Response
-
批准号:7735357
-
项目类别:
-
资助金额:$44.88万
-
财政年份:--
-
负责人:JAMES B MITCHELL
-
依托单位:
Modulation of Therapeutic Response
-
批准号:7066825
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JAMES B MITCHELL
-
依托单位:
Modulation of Therapeutic Response
-
批准号:6756256
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JAMES B MITCHELL
-
依托单位:
Modulation of Therapeutic Response
-
批准号:6558297
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JAMES B MITCHELL
-
依托单位:
Nitroxides as Protectors Against Oxidative Stress
-
批准号:6558332
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JAMES B MITCHELL
-
依托单位:
Nitroxides as Protectors Against Oxidative Stress
-
批准号:6756263
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JAMES B MITCHELL
-
依托单位:
Nitroxides as Protectors Against Oxidative Stress
-
批准号:7735362
-
项目类别:
-
资助金额:$44.88万
-
财政年份:--
-
负责人:JAMES B MITCHELL
-
依托单位:
MODULATION OF THERAPEUTIC RESPONSE
-
批准号:6290743
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JAMES B MITCHELL
-
依托单位:
Nitroxides as Protectors Against Oxidative Stress
-
批准号:6433348
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JAMES B MITCHELL
-
依托单位:
海外基金